Sunday - July 20, 2025
ALPHARETTA, Ga., Nov. 5, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced the launch of its newly designed CORGRIP SR Nasogastric/Nasointestinal Tube Retention System, further expanding its comprehensive Enteral Feeding portfolio.
The new CORGRIP SR system, featuring a monofilament thread, is a nasal bridle solution designed to offer numerous advantages over tape. CORGRIP SR is designed to reduce the risk of dislodgement and the complications associated with replacement of nasal tubes.
CORGRIP SR also enhances visibility and flexibility. The product includes several new features, such as a yellow tipped retrieval catheter with a hollow tip, color-coded clips, printed centimeter markings and a unique orange opening tool.
"Research shows that 40%-63% of feeding tubes secured with tape become inadvertently dislodged," says Kerr Holbrook, chief commercial officer. "Using a bridle to secure feeding tubes significantly reduces the incidence of accidental tube removal and improves overall tube survival rates."
Healthcare professionals interested in learning more about CORGRIP SR or scheduling an onsite demonstration are encouraged to visit https://avanosmedicaldevices.com/digestive-health/enteral-feeding/corgrip-sr/
About Avanos Medical, Inc.
Avanos Medical (NYSE: AVNS) is a medical technology company focused on delivering clinically superior solutions that will help patients get back to the things that matter. Headquartered in Alpharetta, Georgia, Avanos is committed to addressing some of today's most important healthcare needs, including providing a vital lifeline for nutrition to patients from hospital to home, and reducing the use of opioids while helping patients move from surgery to recovery. Avanos develops, manufactures and markets its recognized brands globally and holds leading market positions in multiple categories across its portfolio. For more information, visit www.avanos.com and follow Avanos Medical on X (@AvanosMedical), LinkedIn and Facebook.
Last Trade: | US$11.22 |
Daily Change: | -0.45 -3.86 |
Daily Volume: | 436,660 |
Market Cap: | US$518.810M |
June 09, 2025 May 06, 2025 February 26, 2025 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load